2021
PATH-38. APC MUTATION AS A DRIVER ONCOGENE IN NON-CTNNB1 MUTANT ADAMANTINOMATOUS CRANIOPHARYNGIOMAS
Hong C, Erson-Omay Z, Omay S. PATH-38. APC MUTATION AS A DRIVER ONCOGENE IN NON-CTNNB1 MUTANT ADAMANTINOMATOUS CRANIOPHARYNGIOMAS. Neuro-Oncology 2021, 23: vi123-vi123. PMCID: PMC8598823, DOI: 10.1093/neuonc/noab196.490.Peer-Reviewed Original ResearchAdamantinomatous craniopharyngiomaInstitutional review board-approved protocolCTNNB1 mutationsFamilial adenomatous polyposisWhole-exome sequencingAPC mutationsNeurological deficitsVentricular involvementOptic apparatusClassic subtypeStop codon mutationMalignant tumorsThird ventricleBRAF inhibitorsCraniopharyngeal ductDriver oncogenesTherapeutic strategiesMAP kinase/ERKCraniopharyngiomaGermline APC mutationsPapillary craniopharyngiomasPituitary glandAdenomatous polyposisPathogenic variantsEmbryonic remnants
2017
Do craniopharyngioma molecular signatures correlate with clinical characteristics?
Omay SB, Chen YN, Almeida JP, Ruiz-Treviño AS, Boockvar JA, Stieg PE, Greenfield JP, Souweidane MM, Kacker A, Pisapia DJ, Anand VK, Schwartz TH. Do craniopharyngioma molecular signatures correlate with clinical characteristics? Journal Of Neurosurgery 2017, 128: 1473-1478. PMID: 28707994, DOI: 10.3171/2017.1.jns162232.Peer-Reviewed Original ResearchConceptsPapillary craniopharyngiomasAdamantinomatous craniopharyngiomaMutation groupPostoperative clinical symptomsSubgroup of tumorsMolecular signaturesWeill Cornell Medical CollegeND tumorsClinical characteristicsCornell Medical CollegeClinical symptomsClinical variablesGroup tumorsRadiographic featuresResults HistologyBRAF mutationsCraniopharyngiomaAge groupsMedical CollegeTumorsExome sequencing studiesCTNNB1 mutationsOutcome variablesHistologyPatients